Buy CKPT 26/10/2021You can buy CKPT target 3.56 stop loss 3.03
Money management your responsibility.
I recommend entering a maximum of 10% of the portfolio.
Good luck
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.50 USD
−51.85 M USD
103.00 K USD
37.36 M
About Checkpoint Therapeutics, Inc.
Sector
CEO
James F. Oliviero
Headquarters
Waltham
Website
Founded
2014
FIGI
BBG00F5TPW72
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
CKPT making bullish movesCKPT has been in an upward trend since March last year and has recently broken out of a long negative trend, completing a cup pattern on the daily chart. I would expect it to perform a handle over the next few sessions to confirm the pattern, then continue its upward trajectory.
The daily RSI is a
$CKPT Checkpoint $3.50 target Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on No
CKPT: Ascending Triangle, ConfirmedAscending Triangle, confirmed
Pros:
R/R ratio high, above 6
Descending volume during formation
Volume spike at break out
PPS above 50Ma and 200MA
250RSI above 50
ATR ascending, more volatiliy
RS above 0 and ascending
200MA ascending
Price Target:
PT = 4.00$
No resistance above
Breakout of falling wedge
1) Breakout of falling wedge
2) Cloud turned bullish
3) EMA crossover on daily and weekly
4) High bullish volume
CKPT - BREAKOUT - UPDATECKPT is breaking out on heavy volume.
Primary Wave 1 Extension
Daily:
Levels:
Target:
CKPT - Flag formation long from $4 to $4.83CKPT is purely a technical setup. It seems formed a beautiful Flag formation. It has beautiful money flow divergence. We think it will continue upward from here.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CKPT is 3.37 USD — it has increased by 2.67% in the past 24 hours. Watch Checkpoint Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Checkpoint Therapeutics, Inc. stocks are traded under the ticker CKPT.
CKPT stock has fallen by −5.72% compared to the previous week, the month change is a 39.52% rise, over the last year Checkpoint Therapeutics, Inc. has showed a 77.37% increase.
We've gathered analysts' opinions on Checkpoint Therapeutics, Inc. future price: according to them, CKPT price has a max estimate of 27.00 USD and a min estimate of 4.00 USD. Watch CKPT chart and read a more detailed Checkpoint Therapeutics, Inc. stock forecast: see what analysts think of Checkpoint Therapeutics, Inc. and suggest that you do with its stocks.
CKPT reached its all-time high on Feb 28, 2017 with the price of 150.00 USD, and its all-time low was 1.30 USD and was reached on Sep 26, 2023. View more price dynamics on CKPT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CKPT stock is 8.20% volatile and has beta coefficient of 1.29. Track Checkpoint Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Checkpoint Therapeutics, Inc. there?
Today Checkpoint Therapeutics, Inc. has the market capitalization of 155.76 M, it has increased by 5.23% over the last week.
Yes, you can track Checkpoint Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Checkpoint Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
CKPT earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.30 USD resulting in a 40.98% surprise. The estimated earnings for the next quarter are −0.15 USD per share. See more details about Checkpoint Therapeutics, Inc. earnings.
Checkpoint Therapeutics, Inc. revenue for the last quarter amounts to 41.00 K USD, despite the estimated figure of 15.50 K USD. In the next quarter, revenue is expected to reach 20.33 K USD.
CKPT net income for the last quarter is −6.67 M USD, while the quarter before that showed −10.95 M USD of net income which accounts for 39.06% change. Track more Checkpoint Therapeutics, Inc. financial stats to get the full picture.
No, CKPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 23.00 employees. See our rating of the largest employees — is Checkpoint Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Checkpoint Therapeutics, Inc. EBITDA is −35.49 M USD, and current EBITDA margin is −50.63 K%. See more stats in Checkpoint Therapeutics, Inc. financial statements.
Like other stocks, CKPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Checkpoint Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Checkpoint Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Checkpoint Therapeutics, Inc. stock shows the neutral signal. See more of Checkpoint Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.